natgillin/translations-raw huggingface dataset:
• Co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g. ketoconazole, 
• Istodobna primjena tikagrelora s jakim inhibitorima CYP3A4 (npr. ketokonazol,
Co-administration of ticagrelor with potent CYP3A inducers may decrease exposure and efficacy of ticagrelor, therefore, their concomitant use with ticagrelor is discouraged. 
Istodobna primjena tikagrelora s potentnim induktorima CYP3A može smanjiti izloženost tikagreloru i njegovu djelotvornost, pa se njihova istodobna primjena s tikagrelorom ne preporučuje.
TIMI Major: Fatal bleeding, OR any intracranial bleeding, OR clinically overt signs of haemorrhage associated with a drop in haemoglobin (Hgb) of ≥50 g/L, or when Hgb is not available, a fall in haematocrit (Hct) of 15%. 
TIMI velika: Fatalno krvarenje, ILI bilo koje intrakranijalno krvarenje, ILI klinički jasni znakovi krvarenja povezanog sa smanjenjem hemoglobina (Hgb) od ≥50 g/l, ili, kada Hgb nije dostupan, smanjenjem hematokrita (Hct) od 15%.
Following an oral ticagrelor 90 mg single dose under fasted conditions in healthy subjects, Cmax is 529 ng/ml and AUC is 3451 ng*h/ml. 
Nakon peroralne primjene jednokratne doze tikagrelora od 90 mg na prazan želudac u zdravih ispitanika, Cmax je 529 ng/ml, a AUC je 3451 ng*h/ml.
Other PLATO Major 
Ostala PLATO velika
Due to reports of cutaneous bleeding abnormalities with SSRIs (e.g. paroxetine, sertraline and citalopram), caution is advised when administering SSRIs with ticagrelor as this may increase the risk of bleeding. 
Zbog prijavljenih kožnih krvarenja prilikom primjene lijekova iz skupine selektivnih inhibitora ponovne pohrane serotonina (npr. paroksetin, sertralin i citalopram), potreban je oprez pri primjeni ovih lijekova s tikagrelorom s obzirom da to može povećati rizik od krvarenja.
• digoxin (used to treat heart failure) 
• digoksin (za liječenje zatajenja srca),
In PLATO patients undergoing coronary artery bypass grafting (CABG), ticagrelor had more bleeding than clopidogrel when stopped within 1 day prior to surgery but a similar rate of major bleeds compared to clopidogrel after stopping therapy 2 or more days before surgery (see section 4.8). 
Kod bolesnika u studiji PLATO koji su bili podvrgnuti ugrađivanju aortokoronarne premosnice (CABG), tikagrelor je pokazao više krvarenja nego klopidogrel kada se prestao primjenjivati 1 dan prije operacije, ali je broj velikih krvarenja u usporedbi s klopidogrelom bio sličan ako se prestao primjenjivati 2 ili više dana prije operacije (vidjeti dio 4.8).
CI = Confidence interval; CV = Cardiovascular; HR = Hazard ratio; KM = Kaplan-Meier; MI = Myocardial infarction; N = Number of patients. 
CI = interval pouzdanosti; KV = kardiovaskularni; HR = omjer hazarda; KM = Kaplan-Meier; IM = infarkt miokarda; N = broj bolesnika.
Paediatric population Ticagrelor has not been evaluated in a paediatric population (see sections 4.2 and 5.1). 
Pedijatrijska populacija Tikagrelor nije procjenjivan među pedijatrijskom populacijom (vidjeti dijelove 4.2 i 5.1).
Both 60 mg twice daily and 90 mg twice daily regimens of ticagrelor in combination with ASA were superior to ASA alone in the prevention of atherothrombotic events (composite endpoint: CV death, MI and stroke), with a consistent treatment effect over the entire study period, yielding a 16% RRR and 1.27% ARR for ticagrelor 60 mg and a 15% RRR and 1.19% ARR for ticagrelor 90 mg. 
Oba režima tikagrelora, 60 mg dvaput dnevno i 90 mg dvaput dnevno, u kombinaciji s acetilsalicilatnom kiselinom bili su superiorni u odnosu na terapiju samo acetilsalicilatnom kiselinom u prevenciji aterotrombotskih događaja (kompozitni ishod: KV smrt, IM i moždani udar), uz dosljedan učinak liječenja tijekom cijelog perioda ispitivanja, rezultirajući sa 16% RRR i 1,27% ARR za tikagrelor 60 mg te 15% RRR i 1,19% ARR za tikagrelor 90 mg.
Interference with platelet function tests to diagnose heparin induced thrombocytopenia (HIT) In the heparin induced platelet activation (HIPA) test used to diagnose HIT, anti-platelet factor 4/heparin antibodies in patient serum activate platelets of healthy donors in the presence of heparin. 
U testu aktivacije trombocita inducirane heparinom (engl. heparin induced platelet activation, HIPA), koji se koristi za dijagnosticiranje heparinom inducirane trombocitopenije (HIT), protutijela na kompleks trombocitnog faktora 4 i heparina u serumu bolesnika aktiviraju trombocite zdravih darivatelja u prisutnosti heparina.
Other strong inhibitors of CYP3A4 (clarithromycin, nefazodone, ritonavir and atazanavir) would be expected to have similar effects and therefore concomitant use of strong CYP3A4 inhibitors with ticagrelor is contraindicated (see section 4.3). 
Očekuje se da bi drugi jaki inhibitori CYP3A4 (klaritromicin, nefazodon, ritonavir i atazanavir) imali slične učinke i stoga je istodobna primjena jakih inhibitora CYP3A4 s tikagrelorom kontraindicirana (vidjeti dio 4.3)
The use of ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial haemorrhage, and in patients with severe hepatic impairment (see section 4.3). 
Primjena tikagrelora kontraindicirana je kod bolesnika s aktivnim patološkim krvarenjem, kod bolesnika s intrakranijalnim krvarenjem u anamnezi, te kod bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).
Ticagrelor as crushed tablets mixed in water, given orally or administered through a nasogastric tube into the stomach, has a comparable bioavailability to whole tablets with regards to AUC and Cmax for ticagrelor and the active metabolite. 
Tikagrelor u obliku smrvljenih tableta promiješanih u vodi, primijenjenih kroz usta ili kroz nazogastričnu cijev u želudac, ima usporedivu bioraspoloživost cijelim tabletama s obzirom na AUC i Cmax za tikagrelor i aktivni metabolit.
A combined efficacy and safety composite (CV death, MI, stroke, or PLATO-defined ‘Total Major' bleeding) indicates that the benefit in efficacy of ticagrelor compared to clopidogrel is not offset by the major bleeding events (ARR 1.4%, RRR 8%, HR 0.92; p=0.0257) over 12 months after ACS. 
Rezultati djelotvornosti i sigurnosti primjene koji se odnose na kombinacije događaja (KV smrti, IM, moždanog udara ili PLATO definiranih „ukupnih velikih“ krvarenja) pokazuju da se prednosti u djelotvornosti tikagrelora u odnosu na klopidogrel ne smanjuju zbog incidencije većih krvarenja (ARR 1,4%, RRR 8%, HR 0,92; p=0,0257) tijekom razdoblja od 12 mjeseci nakon ACS-a.
Caution is advised in patients with history of hyperuricaemia or gouty arthritis. 
Preporučuje se oprez kod bolesnika s hiperuricemijom ili s uričnim artritisom u anamnezi.
In addition, caution should be exercised when administering ticagrelor concomitantly with medicinal products known to induce bradycardia. 
Nadalje, potreban je oprez prilikom istodobne primjene tikagrelora s lijekovima za koje se zna da uzrokuju bradikardiju.
For ticagrelor, 0.9% of patients discontinued study drug because of dyspnoea compared with 0.1% taking clopidogrel. 
Za tikagrelor, 0,9% bolesnika je prestalo s uzimanjem ispitivane djelatne tvari zbog dispneje u usporedbi s 0,1% bolesnika koji su uzimali klopidogrel.
What Brilique is used for 
Za što se Brilique koristi
There were no adverse clinical consequences associated with this imbalance (including syncope or pacemaker insertion) in this patient population (see section 5.1). 
Nije bilo neželjenih kliničkih posljedica povezanih s tim poremećajem (uključujući nesvjesticu ili ugradnju srčanog elektrostimulatora) u toj populaciji bolesnika (vidjeti dio 5.1).
Bleeding findings in PEGASUS Overall outcome of bleeding events in the PEGASUS study are shown in Table 3. 
Ukupni ishod učestalosti krvarenja u studiji PEGASUS je prikazan u tablici 3.
Effects of ticagrelor on other medicinal products 
Učinci tikagrelora na druge lijekove
The treatment effect of ticagrelor over clopidogrel appears consistent across many subgroups, including weight; sex; medical history of diabetes mellitus, transient ischaemic attack or non-haemorrhagic stroke, or revascularisation; concomitant therapies including heparins, GpIIb/IIIa inhibitors and proton pump inhibitors (see section 4.5); final index event diagnosis (STEMI, NSTEMI or UA); and treatment pathway intended at randomisation (invasive or medical). 
Terapijski učinak tikagrelora nad klopidogrelom je konzistentan u mnogim podskupinama, uključujući tjelesnu težinu; spol; šećernu bolest, prolazne ishemijske napade ili ne-hemoragični moždani udar ili ponovnu vaskularizaciju u anamnezi; istodobnu terapiju uključujući heparine, inhibitore GpIIb/IIIa i inhibitore protonske pumpe (vidjeti dio 4.5); konačni indeks događaja po dijagnozi (STEMI, NSTEMI ili nestabilna angina); i smjer liječenja predviđen pri randomizaciji (invazivni ili medikamentozni).
As in PLATO, most reported dyspnoea was mild to moderate in intensity (see section 4.4). 
Kao i u studiji PLATO, najviše prijavljenih događaja dispneje bilo je blage do umjerene jačine (vidjeti dio 4.4).
In PEGASUS, TIMI Major bleeding for ticagrelor 60 mg twice daily was higher than for ASA alone. 
U studiji PEGASUS, TIMI velika krvarenja bila su češća za tikagrelor od 60 mg dvaput dnevno nego za samo acetilsalicilatnu kiselinu.
Co-administration of rifampicin with ticagrelor decreased ticagrelor Cmax and AUC by 73% and 86%, respectively. 
Istodobna primjena rifampicina s tikagrelorom je smanjila Cmax i AUC tikagrelora za 73%, odnosno za 86%.
However, no evidence of clinically significant adverse reactions was observed in the PLATO trial after concomitant administration with one or more medicinal products known to induce bradycardia (e.g. 96% beta blockers, 33% calcium channel blockers diltiazem and verapamil and 4% digoxin). 
Međutim, nisu uočeni dokazi o klinički značajnim nuspojavama tijekom studije PLATO nakon istodobne primjene s jednim ili više lijekova za koje se zna da potiču bradikardiju (npr. 96% beta blokatori, 33% blokatori kalcijevih kanala diltiazem i verapamil i 4% digoksin).
In PEGASUS, a reversible increase in mean serum uric acid levels of 6.3% and 5.6% was found for ticagrelor 90 mg and 60 mg, respectively, compared to a 1.5% decrease in the placebo group. 
U studiji PEGASUS, zapaženo je reverzibilno povećanje srednje serumske razine uratne kiseline od 6,3% odnosno 5,6% za tikagrelor od 90 mg odnosno 60 mg, u usporedbi sa smanjenjem od 1,5% u skupini koja je primala placebo.
Premature discontinuation with any antiplatelet therapy, including Brilique, could result in an increased risk of cardiovascular (CV) death, MI or stroke due to the patient's underlying disease. 
Prijevremeni prestanak uzimanja antitrombocitne terapije, uključujući i Brilique, može rezultirati povećanim rizikom od smrti uslijed kardiovaskularnog zatajenja, infarkta miokarda ili moždanog udara zbog postojeće bolesti.
Al/Al perforated unit dose blister of 8 or 10 tablets; cartons of 10 x 1 tablets (1 blister), cartons of 56 x 1 tablets (7 blisters) and cartons of 60 x 1 tablets (6 blisters). 
Al/Al perforirani blisteri s jediničnim dozama sa 8 ili 10 tableta; kutije sa 10x1 tabletom (1 blister), kutije sa 56x1 tabletom (7 blistera) i kutije sa 60x1 tabletom (6 blistera).
In PLATO, dyspnoea adverse events (AEs) (dyspnoea, dyspnoea at rest, dyspnoea exertional, dyspnoea paroxysmal nocturnal and nocturnal dyspnoea), when combined, was reported by 13.8% of patients treated with ticagrelor and by 7.8% of patients treated with clopidogrel. 
U studiji PLATO, štetni događaj dispneju (dispneja, dispneja u mirovanju, dispneja uslijed fizičkog napora, paroksizmalna noćna dispneja i noćna dispneja), sve zajedno, je prijavilo 13,8% bolesnika liječenih tikagrelorom i 7,8% bolesnika liječenih klopidogrelom.
Therefore, due to the limited clinical experience, ticagrelor should be used with caution in these patients (see section 5.1). 
Stoga se kod ovih bolesnika tikagrelor treba koristiti s oprezom zbog ograničenog kliničkog iskustva (vidjeti dio 5.1).
Patients who reported dyspnoea tended to be older and more frequently had dyspnoea, COPD or asthma at baseline. 
Bolesnici koji su prijavljivali dispneju češće su bili starije dobi i češće su na početku ispitivanja imali dispneju, KOPB ili astmu.
14 film-coated tablets 56 film-coated tablets 60 film-coated tablets 168 film-coated tablets 180 film-coated tablets 
14 filmom obloženih tableta 56 filmom obloženih tableta 60 filmom obloženih tableta 168 filmom obloženih tableta 180 filmom obloženih tableta
Medicinal products metabolised by CYP3A4 
Lijekovi koje metabolizira CYP3A4
• Moderate CYP3A4 inhibitors - Co-administration of diltiazem with ticagrelor increased the ticagrelor Cmax by 69% and AUC to 2.7-fold and decreased the active metabolite Cmax by 38% and AUC was unchanged. 
• Umjereni inhibitori CYP3A4 - istodobna primjena diltiazema s tikagrelorom je povećala Cmax tikagrelora za 69% i AUC tikagrelora 2,7 puta, i smanjila Cmax aktivnog metabolita za 38%, a AUC je ostao nepromijenjen.
Ticagrelor has not been studied in patients with severe hepatic impairment and its use in these patients is therefore contraindicated (see section 4.3). 
Tikagrelor nije ispitivan kod bolesnika s teškim oštećenjem funkcije jetre, stoga je njegova uporaba kod ovih bolesnika kontraindicirana (vidjeti dio 4.3).
Co-administration of ticagrelor and CYP3A4 substrates with narrow therapeutic indices (i.e. cisapride or ergot alkaloids) is not recommended, as ticagrelor may increase the exposure to these medicinal products. 
Ne preporučuje se istodobna primjena tikagrelora i supstrata CYP3A4 s uskom terapijskom širinom (npr. cisaprid ili ergot alkaloidi), budući da tikagrelor može povećati izloženost ovim lijekovima.
In PLATO, the frequency of gouty arthritis was 0.2% for ticagrelor vs. 0.1% for clopidogrel. 
U studiji PLATO, učestalost uričnog artritisa bila je 0,2% za tikagrelor u odnosu na 0,1% za klopidogrel.
Other moderate CYP3A4 inhibitors (e.g. amprenavir, aprepitant, erythromycin and fluconazole) would be expected to have a similar effect and can as well be co-administered with ticagrelor. 
Drugi umjereni inhibitori CYP3A4 (npr. amprenavir, aprepitant, eritromicin i flukonazol) bi očekivano imali slične učinke i mogu se istodobno primjenjivati s tikagrelorom.
Available pharmacodynamic/toxicological data in animals have shown excretion of ticagrelor and its active metabolites in milk (see section 5.3). 
Dostupni farmakodinamički/toksikološki podaci u životinja pokazuju da se tikagrelor i njegovi aktivni metaboliti izlučuju u majčino mlijeko (za detalje vidjeti dio 5.3).
The PEGASUS TIMI-54 study was a 21,162 patient, event-driven, randomised, double-blind, placebo-controlled, parallel group, international multicentre study to assess the prevention of atherothrombotic events with ticagrelor given at 2 doses (either 90 mg twice daily or 60 mg twice daily) combined with low dose ASA (75-150 mg), compared to ASA therapy alone in patients with history of MI and additional risk factors for atherothrombosis. 
Studija PEGASUS TIMI-54 je bila događajima uvjetovana, randomizirana, dvostruko slijepa, placebom kontrolirana, međunarodna, multicentrična studija s paralelnim skupinama koja je uključivala 21162 bolesnika, za procjenu prevencije aterotrombotskih događaja s tikagrelorom primjenjivanim u 2 doze (ili 90 mg dvaput dnevno ili 60 mg dvaput dnevno) u kombinaciji s acetilsalicilatnom kiselinom (75 - 150 mg), u usporedbi s terapijom samo acetilsalicilatnom kiselinom u bolesnika s infarktom miokarda u anamnezi i dodatnim rizičnim faktorima za aterotrombozu.
• Atorvastatin - Co-administration of atorvastatin and ticagrelor increased atorvastatin acid Cmax by 23% and AUC by 36%. 
• Atorvastatin - istodobna primjena atorvastatina i tikagrelora je povećala Cmax atorvastatinske kiseline za 23% i AUC atorvastatinske kiseline za 36%.
Relative to ASA alone, ticagrelor 60 mg twice daily significantly reduced the primary composite endpoint of CV death, MI and stroke. 
U odnosu na terapiju samo acetilsalicilatnom kiselinom, tikagrelor od 60 mg dvaput dnevno značajno je smanjio primarni kompozitni ishod KV smrti, IM i moždanog udara.
• standard blisters (with sun/moon symbols) in cartons of 60 and 180 tablets 
• standardnim blisterima (sa simbolima sunca i mjeseca) u kutijama sa 60 i 180 tableta
However, no evidence of clinically significant adverse reactions was observed in the PLATO trial after concomitant administration with one or more medicinal products known to induce bradycardia (e.g. 96% beta blockers, 33% calcium channel blockers diltiazem and verapamil and 4% digoxin) (see section 4.5). 
Međutim, nisu primijećeni nikakvi dokazi za klinički značajne nuspojave u studiji PLATO nakon istodobne primjene jednog ili više lijekova za koje se zna da uzrokuju bradikardiju (npr. 96% beta blokatori, 33% antagonisti kalcijevih kanala diltiazem i verapamil i 4% digoksin) (vidjeti dio 4.5).
Traumatic and procedural ICHs showed a minor increase with ticagrelor 60 mg treatment, (n=15, 0.2%) compared with ASA therapy alone (n=10, 0.1%). 
Za traumatska i proceduralna intrakranijalna krvarenja pokazano je malo povećanje za tikagrelor od 60 mg (n = 15, 0,2%), u usporedbi s terapijom samo acetilsalicilatnom kiselinom (n = 10, 0,1%).
RRR a (%) (95% CI) 
a(%) (95% CI)
• other medicines such as ketoconazole (used to treat fungal infections), clarithromycin (used to treat bacterial infections), nefazodone (an antidepressant), ritonavir and atazanavir (used to treat HIV infection and AIDS), cisapride (used to treat heartburn), ergot alkaloids (used to treat migraines and headaches). 
• drugi lijekovi kao što su ketokonazol (za liječenje gljivičnih infekcija), klaritromicin (za liječenje bakterijskih infekcija), nefazodon (antidepresiv), ritonavir i atazanavir (koristi se za liječenje infekcije HIV-om i SIDA-e), cisaprid (za liječenje žgaravice), ergot alkaloidi (za liječenje migrena i glavobolja).
Safety Endpoints 
Sigurnosni ishodi
• Your doctor may require a sample of your blood for diagnostic tests if they suspect a rare platelet disorder caused by heparin. 
• Ako Vaš liječnik posumnja na rijedak poremećaj trombocita uzrokovan heparinom, možda će mu trebati uzorak Vaše krvi za dijagnostičke pretrage.
Patients self-identified as black had an 18% lower bioavailability of ticagrelor compared to Caucasian patients, in clinical pharmacology studies, the exposure (Cmax and AUC) to ticagrelor in Japanese subjects was approximately 40% (20% after adjusting for body weight) higher compared to that in Caucasians. 
Bolesnici koji se smatraju crncima imaju 18% manju bioraspoloživost tikagrelora u usporedbi s bolesnicima bijele rase, u kliničkim farmakološkim ispitivanjima, izloženost (Cmax i AUC) tikagreloru kod ispitanika japanskog podrijetla bila je približno 40% (20% nakon prilagodbe tjelesne težine) viša u usporedbi s onom kod bijelaca.
Patients were eligible to participate if they were aged 50 years or over, with a history of MI (1 to 3 years prior to randomisation), and had at least one of the following risk factors for atherothrombosis: age ≥65 years, diabetes mellitus requiring medication, a second prior MI, evidence of multivessel CAD or chronic non-end-stage renal dysfunction. 
Za sudjelovanje u studiji bili su podobni bolesnici u dobi od 50 ili više godina, s IM u anamnezi (1 do 3 godine prije randomizacije) te koji su imali najmanje jedan od sljedećih rizičnih čimbenika za aterotrombozu: dob ≥65 godina, diabetes mellitus kojeg je potrebno liječiti, drugi prethodni IM, dokaz bolesti koronarnih arterija koja zahvaća višestruke krvne žile ili kronično oštećenje funkcije bubrega koje nije u završnom stadiju.
The use of ticagrelor in patients at known increased risk for bleeding should be balanced against the benefit in terms of prevention of atherothrombotic events (see sections 4.8 and 5.1). 
Primjenu tikagrelora kod bolesnika s poznatim povećanim rizikom od krvarenja treba procijeniti u odnosu na korist u smislu prevencije aterotrombotskih događaja (vidjeti dijelove 4.8 i 5.1).
10 x 1 orodispersible tablets 56 x 1 orodispersible tablets 60 x 1 orodispersible tablets 
10x1 raspadljiva tableta za usta 56x1 raspadljiva tableta za usta 60x1 raspadljiva tableta za usta
Ticagrelor is a mild CYP3A4 inhibitor. 
Tikagrelor je blagi inhibitor CYP3A4.
In patients with end stage renal disease on haemodialysis AUC and Cmax of ticagrelor 90 mg administered on a day without dialysis were 38% and 51% higher compared to subjects with normal renal function. 
U bolesnika u završnom stadiju bubrežne bolesti na hemodijalizi, AUC i Cmax tikagrelora u dozi od 90 mg primijenjenog u danu bez dijalize bili su 38% i 51% viši u usporedbi sa ispitanicima sa normalnom funkcijom bubrega.
• PVC-PVDC/Al transparent calendar blister (with sun/moon symbols) of 14 tablets; cartons of 14 tablets (1 blister), 56 tablets (4 blisters) and 168 tablets (12 blisters). 
• PVC-PVDC/Al prozirni kalendarski blister (sa simbolima sunca i mjeseca) sa 14 tableta; kutije sa 14 tableta (1 blister), 56 tableta (4 blistera) i 168 tableta (12 blistera).
Adverse reactions are listed by MedDRA System Organ Class (SOC). 
Nuspojave su navedene prema MedDRA-inoj klasifikaciji organskih sustava (SOC, engl.
The increase in ventricular pauses in the acute phase of ACS was more pronounced in ticagrelor patients with history of CHF (9.2% versus 5.4% in patients without CHF history; for clopidogrel patients, 4.0% in those with versus 3.6% in those without CHF history). 
Povećanje u ventrikularnim stankama u akutnoj fazi akutnog koronarnog sindroma bilo je izraženije kod bolesnika koji su primali tikagrelor s kroničnim zatajivanjem srca (KZS) u anamnezi (9,2% u odnosu na 5,4% kod bolesnika bez anamneze KZS; za ispitanike s klopidogrelom 4,0% u onih koji su imali anamnezu KZS u odnosu na 3,6% onih koji je nisu imali).
• Bleeding from your stomach lining (ulcer) 
• Krvarenje iz sluznice želuca (čira)
The inhibition of platelet aggregation (IPA) effect of ticagrelor was independent of dialysis in patients with end stage renal disease and similar to subjects with normal renal function (see section 4.2). 
Učinak tikagrelora na inhibiciju agregacije trombocita (engl. inhibition of platelet aggregation, IPA) bio je neovisan o dijalizi u bolesnika u završnom stadiju bubrežne bolesti i sličan kao u ispitanika sa normalnom funkcijom bubrega (vidjeti dio 4.2).
Eye haemorrhage 
Poremećaji oka
The corresponding numbers in PEGASUS were 9.1%, 8.8% and 5.5% for ticagrelor 90 mg, 60 mg and placebo, respectively. 
Odgovarajuće vrijednosti u studiji PEGASUS bile su 9,1%, 8,8% odnosno 5,5% za tikagrelor u dozi od 90 mg ili 60 mg, odnosno za placebo.
Post procedural haemorrhage, Traumatic bleedings e.g. bleeding from bladder cancer, gastric cancer, colon cancer e.g. increased tendency to bruise, spontaneous haematoma, haemorrhagic diathesis Identified in post-marketing experience Frequencies derived from lab observations (Uric acid increases to >upper limit of normal from baseline below or within reference range. 
Krvarenje nakon zahvata, traumatsko krvarenje npr. krvarenje raka mokraćnog mjehura, raka želuca ili raka debelog crijeva npr. povećana sklonost stvaranju modrica, spontanom hematomu, hemoragijskoj dijatezi Identificirano nakon stavljanja lijeka u promet Učestalosti dobivene iz laboratorijskih pretraga (razina uratne kiseline se povećava do >gornje granice normale u odnosu na početnu vrijednost koja je ispod ili unutar referentnog raspona.
• perforated unit dose blisters in cartons of 10 x 1, 56 x 1 and 60 x 1 orodispersible tablets. 
• perforiranim blisterima s jediničnim dozama u kutiji sa 10x1, 56x1 i 60x1 raspadljivom tabletom za usta.
Ticagrelor 90 mg twice daily (% patients with event) N=9333 
Tikagrelor 90 mg dvaput dnevno (% bolesnika s događajem) N=9333
Hyperuricaemia may occur during treatment with ticagrelor (see section 4.8). 
Pri liječenju tikagrelorom može doći do hiperuricemije (vidjeti dio 4.8.).
• You have had a blood test that showed more than the usual amount of uric acid. 
• Ako ste na krvnim pretragama imali vrijednosti mokraćne kiseline više od uobičajenih.
The steady state volume of distribution of ticagrelor is 87.5 l. Ticagrelor and the active metabolite is extensively bound to human plasma protein (>99.0%). 
Tikagrelor i aktivni metabolit se opsežno vežu za proteine ljudske plazme (> 99,0%).